-

Bruker and TOFWERK Form Strategic Partnership in High-Speed, Ultra-Sensitive Solutions for Applied and Industrial Markets

  • Compact, fast time-of-flight mass spectrometers by TOFWERK optimized for small molecule applications
  • Innovative, on-line chemical ionization techniques for high sensitivity and in situ small molecule detection for stationary and mobile analysis
  • Sensitive, real-time TOF-MS solutions for semiconductor applications, ambient air analysis, cork analysis and diagnostics research from exhaled breath

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation and TOFWERK AG today announced a strategic partnership for high-speed, ultra-sensitive applied and industrial analytical solutions, in conjunction with a Bruker minority investment in TOFWERK.

The partnership provides a basis for technology collaborations to advance instrument capabilities and for the development of novel analytical applications where high speed and ultra-sensitivity matter. TOFWERK expects to leverage Bruker’s commercial scale to accelerate penetration of selected market segments. This includes offering TOFWERK’s compact time-of-flight mass spectrometers (TOF-MS) for small molecule and volatiles analyses that require exceptional speed and sensitivity, as well as mobility and customization.

TOFWERK’s product portfolio includes specialized solutions based on TOF-MS analyzers and a variety of ionization methods, including real-time proton transfer reaction (PTR) chemical ionization, SIMS using fast ion beams in scanning electron microscopes (FIB-SEM), and inductively coupled plasma ionization (ICP). Novel point-of-need analytical solutions integrating Bruker’s recently acquired direct analysis in real time (DART) technology with TOF-MS are also on the development roadmap.

TOFWERK’s instruments are used in applications such as ambient air monitoring, breath analysis (for research use only), food and flavor analysis, and for airborne molecular contamination (AMC) monitoring in the semiconductor industry. Small footprints and robust engineering enable powerful TOF-MS analysis in demanding industrial environments and aboard mobile platforms, as well as in laboratory settings.

Mr. Jürgen Srega, President of the Bruker CALID group, said: “We are delighted to partner with TOFWERK to combine our innovations for novel analytical applications on fit-for-purpose scientific tools. Our recently acquired IonSense DART technology coupled to the TOFWERK Vocus CI-TOF-MS platform illustrates our technology synergies for the benefit of applied and industrial market customers in diverse application fields.”

Dr. Katrin Fuhrer, co-founder and CFO of TOFWERK, commented: "We are pleased to partner with Bruker as it allows us to leverage technical and operational synergies to better serve our customers through Bruker’s global commercial and service channels.”

Dr. Marc Gonin, co-founder and CEO of TOFWERK, added: “We are excited to work closely with Bruker to further accelerate the commercialization of compact, high-speed TOF-MS solutions for industrial and applied markets, based on ultra-high sensitivity and point-of-need analysis technologies developed at TOFWERK and Bruker.”

About TOFWERK AG:

TOFWERK is making the world a cleaner place through innovative solutions for chemical analysis. TOFWERK scientists and engineers design, manufacture, and optimize high performance mass spectrometers for new applications to support researchers and industrial customers around the world. TOFWERK instruments offer the speed and sensitivity of time-of-flight mass spectrometry with compact, robust construction to enable use in any environment and flexible design to accelerate new applications. TOFWERK’s product portfolio spans a diverse range of markets, including ambient air monitoring, breath analysis, food and flavor, geological science, material science, and semiconductor manufacturing. Please visit https://www.tofwerk.com/

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.

Contacts

TOFWERK

Media:
Kendra Kimmel
TOFWERK AG Head of Marketing
T: +1 (720) 531 2529
E: kendra@tofwerk.com

Bruker

Media:
Petra Scheffer
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com

Investor Relations:
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 663–3660, ext. 1479
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

TOFWERK

Media:
Kendra Kimmel
TOFWERK AG Head of Marketing
T: +1 (720) 531 2529
E: kendra@tofwerk.com

Bruker

Media:
Petra Scheffer
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com

Investor Relations:
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 663–3660, ext. 1479
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker’s President and CEO, commented: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second h...

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab...

Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...
Back to Newsroom